

Product News

Lonza Extends Industry-Standard HUVEC Product Line

- Clonetics™ HUVECs in EGM™-Plus Growth Media is an improved version with faster proliferation rates than traditional HUVECs in EGM™ Growth Media

Walkersville, MD (USA) / Basel, Switzerland, 7 October 2014 – Lonza, the market leader in primary cells, has expanded its human primary cell portfolio with an improved version of Human Umbilical Vein Endothelial Cells (HUVEC) cultured in the absence of additive vascular endothelial growth factor (VEGF). To support these cells, Lonza has developed the new EGM™-Plus Growth Media Kit.

HUVECs cultured in EGM™-Plus Media are an improved version of Lonza's long-standing seller HUVECs cultured in EGM™ Media. Cells in EGM™-Plus Media offer better proliferation rates in the absence of additive VEGF while maintaining the same high-quality characterization as HUVECs in EGM™ Media.

This recent addition to the portfolio offers better solutions to customers in application areas such as cardiovascular diseases, angiogenesis studies, cancer research and wound healing. VEGF is involved in creation of new blood vessels (angiogenesis). Overexpression of this gene has been linked to solid tumor progression and retinal vascular diseases. HUVECs cultured without VEGF offer extended options to researchers, who can use them to understand the implications of the presence and absence of VEGF.

"Our Clonetics™ HUVECs product line is widely used in disease research due to its consistent quality. Recently, our customers have requested faster cell proliferation rates with an endothelial medium that contains little to no VEGF. EGM™-Plus Growth Media does just that for our customers, who rely on Lonza for their vascular research cell culture needs," Lubna Hussain, Senior Product Manager for Bioscience Research Solutions, said.

Lonza currently offers more than 30 different varieties of primary human endothelial cells, including cells from normal, diabetic type I and II donors. These cells come from tissue sources ranging from heart, lung and skin to reproductive organs.

Further information on HUVECs without VEGF and other primary endothelial cells can be found at www.lonza.com/huvec.

Lonza Group Ltd
Muenchensteinerstrasse 38
4002 Basel, Switzerland

Product News

About Lonza Pharma&Biotech – Bioscience Solutions

Lonza provides the pharma market with the tools life science researchers use to develop and test therapeutics, from basic research to final product release. Lonza's bioscience products and services range from cell culture and discovery technologies for research, to quality control tests and software to ensure product quality. Lonza Bioscience Solutions serves research customers worldwide in pharmaceutical, biopharmaceutical, biotechnology and personal care companies, as well as academic and government research institutions. The company delivers physiologically relevant cell biology solutions, and complete solutions for rapid microbiology. Primary brands include BioWhittaker™, Clonetics™, FlashGel™, MetaPhor™, MycoAlert™, Nucleofection™, NuSieve™, PAGER™, Poietics™ and SeaKem®.

About Lonza

Lonza is one of the world's leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. We harness science and technology to create products that support safer and healthier living and that enhance the overall quality of life.

Not only are we a custom manufacturer and developer, Lonza also offers services and products ranging from active pharmaceutical ingredients and stem-cell therapies to drinking water sanitizers, from the vitamin B compounds and organic personal care ingredients to agricultural products, and from industrial preservatives to microbial control solutions that combat dangerous viruses, bacteria and other pathogens.

Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 40 major manufacturing and R&D facilities and approximately 10,000 employees worldwide. The company generated sales of about CHF 3.6 billion in 2013 and is organized into two market-focused segments: Pharma&Biotech and Specialty Ingredients. Further information can be found at www.lonza.com.

Lonza Contact Information

Lonza Cologne GmbH
Marketing Communications and Product PR
Corinna König-Wildförster
Phone: +49 221 99199 464
Fax +49 221 99199 498
pr.cologne@lonza.com

Lonza Group Ltd
Head External Communications
Constance Ward
Phone: +41 61 316 8840
Fax: +41 61 316 9840
constance.ward@lonza.com

Lonza Group Ltd
Muenchensteinerstrasse 38
4002 Basel, Switzerland

Product News

Additional Information and Disclaimer

Lonza Group Ltd is headquartered in Basel, Switzerland, and is listed on the SIX Swiss Exchange and secondary listed on the Singapore Exchange Securities Trading Limited ("SGX-ST"). Lonza Group Ltd is not subject to the SGX-ST's continuing listing requirements. Lonza Group Ltd is subject to the listing rules of the SIX Swiss Exchange, which does not have specific requirements equivalent to the listing rules of the SGX-ST for interested person transactions, acquisition and realizations and delisting.

Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.